Is Confirmatory Biopsy Still Necessary for Active Surveillance of Men With Grade Group 1 Prostate Cancer in the Era of Multiparametric MRI?
Reclassification rates at CBx were high in men with positive MRI, but < 10% for all reclassification outcomes in men with negative MRI (95% CI, 5.8%-14% for GG <u>≥</u>2; 95% CI, 2.9%-10% for UIR; 95% CI, 0.8%-5.3% for GG <u>≥</u>3). Our data support systematic + targeted CBx for men with positive MRI considering AS, whereas men with GG1 cancer and negative MRI should be able to defer CBx.
Authors
- Yasin Bhanji
- Mufaddal K. Mamawala (ORCID: https://orcid.org/0000-0002-5161-3769)
- Katarzyna J. Macura (ORCID: https://orcid.org/0000-0002-8469-2125)
- Hiten D. Patel (ORCID: https://orcid.org/0000-0003-4028-010X)
- Christian P. Pavlovich (ORCID: https://orcid.org/0000-0002-8532-0251)
- Sean A. Fletcher (ORCID: https://orcid.org/0000-0001-8267-1948)
- Patricia Landis
Institutions
- Northwestern University (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
Publication Details
- Journal
- The Journal of Urology
- Published
- 2024-10-02
- DOI
- https://doi.org/10.1097/ju.0000000000004268
- Citations
- 4
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.68